Anthera Pharmaceuticals (ANTH) Stock: Climbing On Clinical Update

Anthera Pharmaceuticals Inc ANTH Stock News

Anthera Pharmaceuticals Inc (NASDAQ: ANTH) is having a great trading session in the market today, and for good reason. The company announced the results from a key Phase 3 clinical study. Today, we’ll talk about the results, what we’re seeing from the stock, and what we’ll be watching for with regard to ANTH ahead.

ANTH Gains On Phase 3 Results 

As mentioned above, Anthera Pharmaceuticals is having an incredibly strong day in the market today after announcing a clinical update. In a press release issued early this morning, the company announced a positive outcome of the second, pre-specified interim futility analysis for the RESULT Phase 3 clinical trial.

Leave a Comment